Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Account Payables (2024 - 2025)

Xilio Therapeutics' Change in Account Payables history spans 2 years, with the latest figure at -$1.8 million for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 542.14% year-over-year to -$1.8 million; the TTM value through Sep 2025 reached $1.3 million, changed N/A, while the annual FY2024 figure was $1.5 million, 173.97% up from the prior year.
  • Change in Account Payables for Q3 2025 was -$1.8 million at Xilio Therapeutics, down from $2.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.1 million in Q2 2025 and bottomed at -$1.8 million in Q3 2025.